Abstract
INVESTIGATIONS made to determine the causes of loss of antihæmophilic factor (AHF) during the Blombäck process1 for preparing AHF-rich fibrinogen from large volumes of plasma have revealed that when the starting material is frozen plasma instead of fresh plasma there is a presumed liability which can be converted to an advantage.
Similar content being viewed by others
Article PDF
References
Blombäck, M., Arkiv. Kemi, 12, 387 (1958).
McMillan, C. W., Diamond, L. K., and Surgenor, D. M., New England J. Med., 265, 224 (1961).
Ninth Cong. Intern. Soc. Blood Transfusion, Mexico City (1962).
Pool, J. G., and Robinson, J., Brit. J. Hæmat., 5, 24 (1959).
Pool, J. G., and Robinson, J., Brit. J. Hæmat., 5, 17 (1959).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
POOL, J., HERSHGOLD, E. & PAPPENHAGEN, A. High-potency Antihæmophilic Factor Concentrate prepared from Cryoglobulin Precipitate. Nature 203, 312 (1964). https://doi.org/10.1038/203312a0
Issue Date:
DOI: https://doi.org/10.1038/203312a0